Silenseed round III Silenseed round III נייד

Led by leading scientists, Silenseed has achieved the incredible feat of developing various drugs and therapies that extend and enhance the lives of patients with pancreatic cancer. Their breakthroughs offers hope for individuals effected by one of the most prevalent and deadly diseases worldwide.
Silenseed's comprehensive portfolio encompasses various aspects of RNAi-based treatments and therapeutics, which they hold IP and have been granted patents for (See Silenseed website).

Type Stocks
Category Bio-tech
Minimum Investment 100


The need for a solution

Pancreatic cancer is known as one of the deadliest cancers, and usually when people are diagnosed with the disease in most cases they are in advanced stages.

Every year, hundreds of thousands of people are diagnosed in the world, and they suffer from severe pain and a deterioration in their quality of life.

The average life expectancy of patients with pancreatic cancer is estimated at about 10 months, and the survival rates are only a few percent.

The best cancer researchers in the world are working on developing a drug or treatment that can benefit the patients, extend their lives and improve their quality.

In 2023, the Biden administration also joined the fight and set a new goal to reduce cancer death rates in the world, but a significant breakthrough in the field has not yet been found.

Pancreatic cancer patients and their families are desperate for treatment that will help prolong their lives and make everyday life easier.

The Innovation the company brings to the medical world

The Silenseed company touches precisely the need of most pancreatic cancer patients in the world. The company is in the process of developing a drug that can extend the lifespan of patients.

The revolution in Silenseed’s drug is that it is based on genetic silencing that stops the continued growth and/or spread of cancer cells to other areas of the body.

The drug, which comes in the form of a liquid injected into the tumor, is suitable for 75% of pancreatic cancer patients and its success can change the course of the disease in hundreds of thousands of patients worldwide.

So far, the company has completed phase 2 of the clinical trials for the “first generation” drug and the results were encouraging and positive. The results will be presented at the ESMO conference later this year.

Facing forward towards the future

The initial phase 2 trial was carried out in collaboration with the leading hospitals in Israel and the United States. It is given as part of a trial that combines well-known international doctors and researchers, and has so far shown promising results

Following the experiment carried out, the company learned that it is necessary to extend the delayed release technology of the drug in the body, for this purpose the company signed an exclusive cooperation agreement with the American pharmaceutical company EVONIK, which specializes in creating drugs with prolonged release in the world. The purpose of the collaboration is to produce a medicine that will last for a long period of time and improve clinical efficiency.

The company’s development is not limited to pancreatic cancer only, the technology will also make it possible to deal with other types of cancer such as lung, breast, prostate, and head cancer, so its potential is huge. In addition, the company has patents registered in its name and valid for another 10-15 years – an element that guarantees it global exclusivity for a long time.

We Are Here For You!